2DALAKAS M C, HOHLFELD R. Polymyositis and dermatomyositis[J].Lancet, 2003, 362 (9388) : 971-982.
3DALAKAS M C. Autoimmune muscular pathologies [ J]. Neurol Sci, 2005, 26 (Suppl 1) : S7-S8.
4VAN DER MEULEN MF, BRONNER I M, HOOGENDIJK J E, et al. Pnlymyositis : an overdiagnosed entity [ J ] . Neurology, 2003, 61 (3): 316-321.
5HOOGENDIJK J, AMATO A, LECKY B, et al.119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with exception of inclusion body myositis [ J ]. Neuromuscul Disord, 2004, 14 (5) : 337-345.
7HENGSTMAN G J, VAN DEN HOOGEN F H, BARRERA P, et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations [. J ] . Eur Neurol, 2003, 50 ( 1 ) : 10-15.
8EFTHIMIOU P, SCHWARTZMAN S, KAGEN L J, et aL Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients[J]. Ann Rheum Dis, 2006, 65 (9): 1233- 1236.
9IANNONE F, SCIOSCIA C, FALAPPONE P C, et at. Use of etanercept in the treatment of dermatomyositis : a case series[ J]. J Rheumatol, 2006, 33 (9) : 1802-1804.
10MUSIAL J, UNDAS A, CELINSKA-LOWENHOFF M. Polymyositis associated with infliximab treatment for rheumatoid arthritis[J]. Rheumatology, 2003, 42 (12): 1566-1568.
3Bayry J, Lacriox-Desmazes S, Carbonneil C, et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood, 2003, 101: 758-765.
4Marchalonis J, Kaymaz H, Dedeoglu F, et al. Human autoantibodies reactive with synthetic autoantigens from T cell receptor Vβchain. Proc Natl Acad Sci USA, 1992, 89: 3325-3329.
5Kaveri S, Vassilev T, Hurex V, et al. Antibodies to a conserved region of HLA class 1 molecules, capable of modulating CD8 Tcell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest, 1996, 97: 868-869.
6Vassilev T, Gelin C, Kaveri S, et al. Antibodies to the CD5molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol, 1993,92: 369-372.
7Wada J, Shintani K, Kikutani T, et al. Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition. Clin Exp Immunol, 2001, 124: 282-289.
8Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest, 1994, 94: 1729-1735.
9Lutz HU, Stammler P, Bianchi V, et al. Intravenously applied IgGstimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood,2004, 103: 465-472.
10Basta M, van Goor F, Luecioli S, et al. F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med, 2003, 9: 431-438.
